CA2899746A1 - Pharmaceutical composition comprising leflunomide - Google Patents
Pharmaceutical composition comprising leflunomide Download PDFInfo
- Publication number
- CA2899746A1 CA2899746A1 CA2899746A CA2899746A CA2899746A1 CA 2899746 A1 CA2899746 A1 CA 2899746A1 CA 2899746 A CA2899746 A CA 2899746A CA 2899746 A CA2899746 A CA 2899746A CA 2899746 A1 CA2899746 A1 CA 2899746A1
- Authority
- CA
- Canada
- Prior art keywords
- leflunomide
- pharmaceutical composition
- arthritis
- eur
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE201310001636 DE102013001636A1 (de) | 2013-01-31 | 2013-01-31 | Pharmazeutische Zusammensetzung umfassend Leflunomid |
DE102013001636.3 | 2013-01-31 | ||
DE102013007106.2 | 2013-04-25 | ||
DE102013007106.2A DE102013007106A1 (de) | 2013-04-25 | 2013-04-25 | Pharmazeutische Zusammensetzung umfassend Leflunomid |
PCT/EP2014/000006 WO2014096464A1 (de) | 2013-01-31 | 2014-01-06 | Pharmazeutische zusammensetzung umfassend leflunomid |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2899746A1 true CA2899746A1 (en) | 2014-06-26 |
Family
ID=49955310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2899746A Abandoned CA2899746A1 (en) | 2013-01-31 | 2014-01-06 | Pharmaceutical composition comprising leflunomide |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2950796A1 (de) |
CA (1) | CA2899746A1 (de) |
WO (1) | WO2014096464A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105287420A (zh) * | 2015-12-03 | 2016-02-03 | 李正梅 | 一种治疗成人类风湿性关节炎的来氟米特片 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624946A (en) * | 1994-07-05 | 1997-04-29 | Williams; James | Use of leflunomide to control and reverse chronic allograft rejection |
DE102005017592A1 (de) * | 2005-04-16 | 2006-10-19 | Lindner, Jürgen, Dr. med. | Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem |
TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
-
2014
- 2014-01-06 WO PCT/EP2014/000006 patent/WO2014096464A1/de active Application Filing
- 2014-01-06 EP EP14700203.4A patent/EP2950796A1/de not_active Ceased
- 2014-01-06 CA CA2899746A patent/CA2899746A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2950796A1 (de) | 2015-12-09 |
WO2014096464A1 (de) | 2014-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2769132C2 (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
TWI732785B (zh) | 雜環化合物及其用途 | |
EP2282779B1 (de) | Neue therapeutische ansätze zur behandlung von alzheimer-krankheit und verwandter erkrankungen durch modulation der stressantwort | |
TWI667025B (zh) | 治療肝臟疾病之方法 | |
CN104870998B (zh) | 对作为TOR激酶抑制活性标记的PRAS40、GSK3‑β或P70S6K1的磷酸化抑制 | |
CN107801378A (zh) | 用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904 | |
US20120282187A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
CN105377299B (zh) | 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法 | |
US20120277269A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
CN107137402A (zh) | 用tor激酶抑制剂治疗癌症 | |
CN107667092A (zh) | 作为fgfr4抑制剂的甲酰化n‑杂环衍生物 | |
Lorrio et al. | Novel multitarget ligand ITH33/IQM9. 21 provides neuroprotection in in vitro and in vivo models related to brain ischemia | |
TW201120042A (en) | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes | |
JP2011525194A (ja) | 線維性疾患または病態を治療するための組成物 | |
CN115073421B (zh) | 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺 | |
UA126977C2 (uk) | Таблетка деферипрону з відтермінованим вивільненням та спосіб її виготовлення | |
Zhang et al. | Pretreatment with metformin prevents microcystin‐LR‐induced tau hyperphosphorylation via mTOR‐dependent PP2A and GSK‐3β activation | |
CN103340860A (zh) | 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法 | |
CA2899746A1 (en) | Pharmaceutical composition comprising leflunomide | |
CN106794180A (zh) | 联合疗法 | |
JP2003531174A (ja) | Pde5インヒビターを使用する勃起機能不全に対する毎日の処置 | |
MXPA04010951A (es) | Nueva combinacion. | |
JP2021504462A (ja) | トロポミオシン受容体キナーゼa(trka)阻害剤としてのピリミジン誘導体 | |
CA3213359A1 (en) | Alk-5 inhibitors and uses thereof | |
KR20190038828A (ko) | 피. 아크네스(P. acnes)에 의해 유발된 염증과 관련된 장애의 예방 및/또는 치료에 사용하기 위한 메클로진 유도체 및 디클라주릴 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20181219 |
|
FZDE | Discontinued |
Effective date: 20220706 |
|
FZDE | Discontinued |
Effective date: 20220706 |